For example, in one study with preclinical models of gemcitabine-resistant pancreatic cancer, HDAC inhibitors showed the ability to significantly restore sensitivity to gemcitabine by unsilencing crucial drug influx transporters [115]. The gene discussed is HDAC9; the disease is pancreatic neoplasm.